Amylyx Pharmaceuticals (AMLX) Enterprise Value (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Enterprise Value of -$279.8 million for Q1 2026, down 37.1% year-over-year from -$444.8 million in Q1 2025, and up 11.74% quarter-over-quarter from -$317.0 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Enterprise Value (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Enterprise Value history runs 6 years deep, the most recent figure standing at -$279.8 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 37.1% year-over-year to -$279.8 million; the TTM figure through Mar 2026 stood at -$279.8 million (down 37.1% YoY), while the FY2025 annual figure was -$317.0 million, down 79.59% from the prior year.
- Enterprise Value for Q1 2026 stood at -$279.8 million, up from -$317.0 million in the prior quarter.
- The five-year high for Enterprise Value was -$162.6 million in Q3 2022, with the low at -$373.3 million in Q1 2024.
- The 5-year median for Enterprise Value is -$309.8 million (2024), against an average of -$283.6 million.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value slumped 260.96% in 2022, then jumped 52.47% in 2024.
- Amylyx Pharmaceuticals' Enterprise Value stood at -$346.9 million in 2022, then decreased by 7.04% to -$371.4 million in 2023, then surged by 52.47% to -$176.5 million in 2024, then plunged by 79.59% to -$317.0 million in 2025, then increased by 11.74% to -$279.8 million in 2026.
- Business Quant data shows AMLX's Enterprise Value at -$279.8 million in Q1 2026, -$317.0 million in Q4 2025, and -$344.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | -882.82 Mn |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | -3.65 Bn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | -1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | -5.79 Bn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | -2.66 Bn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | -886.50 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | -389.80 Mn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | -530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | -164.00 Mn |
| 10 | Amylyx Pharmaceuticals | 4.28 Bn | 4.28 Bn | - | -250.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -250.76 Mn |
| Mar 31, 2026 | -279.77 Mn |
| Dec 31, 2025 | -316.98 Mn |
| Sep 30, 2025 | -343.99 Mn |
| Jun 30, 2025 | -180.83 Mn |
| Mar 31, 2025 | -204.07 Mn |
| Dec 31, 2024 | -176.50 Mn |
| Sep 30, 2024 | -234.40 Mn |
| Jun 30, 2024 | -309.81 Mn |
| Mar 31, 2024 | -373.29 Mn |
| Dec 31, 2023 | -371.36 Mn |
| Sep 30, 2023 | -355.05 Mn |
| Jun 30, 2023 | -357.28 Mn |
| Mar 31, 2023 | -345.67 Mn |
| Dec 31, 2022 | -346.95 Mn |
| Sep 30, 2022 | -162.59 Mn |
| Jun 30, 2022 | -206.68 Mn |
| Mar 31, 2022 | -255.21 Mn |
| Dec 31, 2021 | -96.12 Mn |